About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
MGNX - MacroGenics| Previous Close | $21.74 | Open | $21.60 |
| Volume | 281.7K | Market Cap | 1.195B |
| Yield | Last Dividend |
| Growing M&A momentum drives gains in Rhe... | 10/12/20 |
| Growing M&A momentum drives gains in Rhenman???s flagship healthcare hedge fund Submitted By Hugh Leask | 12/10/2020 - 12:36pm A pick-up in M&A activi... | |
| MacroGenics Provides Update on Corporate... | 07/30/20 |
| Conference call scheduled for today at 4:30 p.m. ET. | |
| MacroGenics Announces Date of Second Qua... | 07/23/20 |
| Rockville, MD, July 23, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering??... | |
| The Daily Biotech Pulse: Intersect ENT J... | 07/08/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbV... | |
| The Daily Biotech Pulse: MediciNova On T... | 06/24/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACA... | |
| Healthcare hedge fund Rhenman eyes furth... | 06/11/20 |
| Healthcare hedge fund Rhenman eyes further gains after second double-digit return Submitted By Hugh Leask | 11/06/2020 - 1:54pm Rhenman & Partners Ass... | |
| The Daily Biotech Pulse: Gilead Signs Ma... | 05/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Acce... | |
| The Daily Biotech Pulse: FDA Approves No... | 05/07/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.) Adve... | |
| MacroGenics Analyst Sees Multiple Source... | 05/06/20 |
| MacroGenics Inc (NASDAQ: MGNX ) reported Tuesday after the close with forecast-beating first-quarter results and said it has adequate cash to operate ... | |
| MacroGenics Provides Update on Corporate... | 05/05/20 |
| Conference call scheduled for today at 4:30 p.m. ET. | |
| The Week Ahead In Biotech: Smid-Cap Earn... | 05/03/20 |
| Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma nam... | |
| MacroGenics EPS beats by $0.28, beats on... | 02/25/20 |
| MacroGenics (NASDAQ:MGNX): FY GAAP EPS of -$3.16 beats by $0.28. Revenue of $64.19M (+6.8% Y/Y) beats by $9.31M. Shares +0.02%. Press Release | |
| The Daily Biotech Pulse: Roche-Spark Dea... | 11/22/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.... | |
| TUESDAY DEADLINE ALERT: The Schall Law F... | 11/12/19 |
| LOS ANGELES--(BUSINESS WIRE)---- $MGNX #MGNX--TUESDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, In... | |
| DEADLINE ALERT: Bragar Eagel & Squire, P... | 11/06/19 |
| NEW YORK, Nov. 6, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that a class actio... | |
| MacroGenics (MGNX) Expected to Beat Earn... | 10/30/19 |
| MacroGenics (MGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the... | |
| Notice of Lead Plaintiff Deadline for Sh... | 10/29/19 |
| SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning MacroGenics business and prospects, resulting in its stock ... | |
| The Daily Biotech Pulse: Melinta Crosses... | 10/25/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 24) ... | |
| MacroGenics, Inc. (MGNX), ViewRay, Inc. ... | 10/18/19 |
| NEW YORK, NY / ACCESSWIRE / October 18, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against... | |
| Implied Volatility Surging for MacroGeni... | 06/06/19 |
| Investors need to pay close attention to MacroGenics (MGNX) stock based on the movements in the options market lately. | |
| Why MacroGenics, Inc. Stock Is Heating U... | 05/16/19 |
| MacroGenics shares jumped in response to another major clinical update today. | |
| Iovance Biotherapeutics leads healthcare... | 05/16/19 |
| No summary available. | |
| Macrogenics upgraded to outperform from ... | 05/03/19 |
| This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the ... | |
| MacroGenics, Inc. (MGNX) CEO Scott Koeni... | 05/02/19 |
| MacroGenics, Inc. (NASDAQ:MGNX) Q1 2019 Results Conference Call May 01, 2019 04:30 PM ET Company Participants Anna Krassowska - Vice President, Invest... | |
| Macrogenics Inc (MGNX) Q1 2019 Earnings ... | 05/01/19 |
| MGNX earnings call for the period ending March 31, 2019. | |
| MacroGenics (MGNX) Reports Q1 Loss, Miss... | 05/01/19 |
| MacroGenics (MGNX) delivered earnings and revenue surprises of -4.21% and -15.69%, respectively, for the quarter ended March 2019. Do the numbers hold... | |
| MacroGenics misses by $0.12, misses on r... | 05/01/19 |
| No summary available. | |
| Automakers, Macau Names And CinemaCon Ac... | 03/31/19 |
| No summary available. | |
| MacroGenics (MGNX) Investor Presentation... | 02/27/19 |
| No summary available. | |
| Sell rating | 10/13/20 |
| Morgan Stanley maintains Underweight rating and raises Price Target from $12.00 to $13.00 | |
| Strong Buy rating | 09/21/20 |
| SVB Leerink maintains Outperform rating and raises Price Target from $35.00 to $38.00 | |
| Hold rating | 08/03/20 |
| Citigroup downgrades from Buy to Neutral rating and raises Price Target from $25.00 to $26.00 | |
| Sell rating | 07/31/20 |
| Morgan Stanley maintains Underweight rating and raises Price Target from $11.00 to $12.00 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Arbitrage Trade Analytics | Royce Wells | 71.00 % | Subscribe |
| Mojo Day Trading | ProTrader Mike | 44.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
